Dementia patients with combinations of Alzheimer’s disease (AD), Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) show significantly different distribution of the protein alpha-synuclein than they would with one diagnosis, according to a presentation during last week’s annual meeting of the American Academy of Neurology (AAN).

The radiology community should disclose all of the uncertainties and certainties associated with mammography screening to the public in order to provide the whole truth, according to an article published online May 1 by the Journal of the American College of Radiology.

An investigational therapy called Neurostem-AD developed by Medipost to treat the neurodegeneration caused by Alzheimer’s disease is currently in clinical trials and is now receiving financial backing from Americord, a cord blood, tissue and placenta bank, Americord officials announced today. 

Biopharmaceutical company Lumiphore, from Berkeley, Calif., has captured a Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to develop novel macrocyclic chelating groups in an effort to create targeted radioisotope drug delivery systems, the company announced in April.

The American Society for Radiation Oncology (ASTRO) is concerned by the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC) April 30, 2014 recommendation to the Centers for Medicare and Medicaid Services (CMS) that adults at high risk for lung cancer should not receive Medicare coverage of annual, low-dose computed tomography (LDCT) screening.

Looking underneath a mummy’s bandages used to require destroying the ancient specimen, which is not an attractive option with such precious remains. Of course, today’s imaging technology can peer inside a human body—mummified or not.

Two researchers received awards of $130,000 each for their work in developing treatments for Alzheimer’s and the movement disorder dystonia based on their research into neurotoxins, according to an announcement from the American Academy of Neurology (AAN) during the organization’s 66th annual meeting in Philadelphia.

Biopharmaceutical giant Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based iPierian for $175 million.